Strategic Insight into the Global Women’s Oncology Diagnostics Market, 2017

Surge in Adoption of Next Generation Sequencing (NGS) Solutions for Predictive Diagnosis Transforms the IVD Testing Landscape
Share this:
Published: 21 Dec 2017

Across the world, women live longer than men. The reason behind the difference between male and female life expectancy is unclear, but it seems related partially to biological advantages and partially to environmental and behavioral factors. Even though women outlive men, they are more prone to suffering from ill health and other age-related diseases. Women's healthcare, however, especially in less-developed settings, remains mostly confined to reproductive issues, particularly maternal health. Attention to other significant women’s health issues such as cardiology, reproductive health, and urology is growing rapidly. Overall, the advancements in women’s health diagnostic products are intense, and diagnostic technologies have been subjected to rapid change. Two of the key market drivers are the rising occurrence of lifestyle disorders among women and growing awareness of women-specific health issues. The other drivers include the rise in the number of private diagnostic labs mostly in the emerging nations, health initiatives/drives taken by governments and other health organizations, and new approvals for easy-to-use rapid tests. Nevertheless, the lack of skillful lab professionals and high set-up costs of diagnostic devices/systems are some key restraints to growth in the women’s health diagnostics market. Currently, women’s health diagnostic products are being targeted at markets outside of the traditional hospital or clinical laboratory. In fact, the demand for home healthcare services in women’s health is facing a steady increase, but, at the same time, there is pressure to lower costs and maintain the high quality of the care delivered at home. Continuous improvements in technology are bringing about a number of new diagnostic tests that consolidate high levels of accuracy with rapid, easy-to-use product designs. Breast cancer is one of the leading causes of death in women across the globe and accounts for almost 3% of total deaths among women. Research suggests that out of every 12 women one will develop breast cancer at some point in her life. The risk factors include hormonal effects, age, and genetic predisposition. Overweight women are considered to be at greater risk for developing breast cancer. With increased weight, greater amounts of estrogen are produced by the body. Just as estrogen in HRT increases breast cancer risk, high amounts of estrogen produced by women before menopause also increase the risk of breast cancer. This strategic research service provides the key growth drivers and current competitive landscape in the women's oncology diagnostics market. Also, it covers the market size and growth rate forecast for 2016 and 2021. Study Scope The women's oncology diagnostics market has been categorized into point-of-care (POC)/molecular tests, lab instrumentation, drug delivery devices, wearables and patient monitoring devices, and surgical instruments. Key Questions This Study Will Answer: What are the key opportunities that make this an attractive market with significant future revenue potential for companies? What is the growth potential for women’s oncology diagnostics solutions and sub-segments across different geographies? What are the key growth drivers that companies should focus on to remain relevant and competitive in this market? Who are the top game-changing companies in the women’s oncology diagnostics market and what are their leading product portfolios?



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..